 |
PDBsum entry 6iqh
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Immune system
|
PDB id
|
|
|
|
6iqh
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
References listed in PDB file
|
|
|
Key reference
|
|
|
Title
|
|
Site-Specific chemical conjugation of antibodies by using affinity peptide for the development of therapeutic antibody format.
|
|
|
Authors
|
|
S.Kishimoto,
Y.Nakashimada,
R.Yokota,
T.Hatanaka,
M.Adachi,
Y.Ito.
|
|
|
Ref.
|
|
Bioconjug Chem, 2019,
30,
698-702.
[DOI no: ]
|
|
|
PubMed id
|
|
|
|
|
|
Abstract
|
|
|
Artificially modified IgG molecules are increasingly utilized in industrial and
clinical applications. In the present study, the method of chemical conjugation
by affinity peptide (CCAP) for site-specific chemical modification has been
developed by using a peptide that bound with high affinity to human IgG-Fc. This
method enabled a rapid modification of a specific residue (Lys248 on Fc) in a
one-step reaction under mild condition to form a stable amide bond between the
peptide and Fc. The monovalent peptide-IgG conjugate not only maintained
complete antigen binding but also bound to Fc receptors (FcRn, FcγRI, and
FcγRIIIa), indicating that it is a suitable conjugate form that can be further
developed into highly functional antibody therapeutics. CCAP was applied for the
preparation of an antibody-drug conjugate and a bispecific antibody to
demonstrate the usefulness of this method.
|
|
|
|
|
|
|
